Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Virus or bacteriophage
Reexamination Certificate
2007-09-04
2007-09-04
Campell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Virus or bacteriophage
C424S093100, C424S215100, C435S320100
Reexamination Certificate
active
10076074
ABSTRACT:
The present invention relates to a method of increasing the sensitivity of neoplastic cells to chemotherapeutic agents by using a virus, a method of treating proliferative disorders with a virus and chemotherapeutic agents, and a method for preventing a neoplasm from developing drug resistance to chemotherapeutic agents. The virus is preferably a reovirus.
REFERENCES:
patent: 6100243 (2000-08-01), Frisch
patent: 6136307 (2000-10-01), Lee et al.
patent: 6565831 (2003-05-01), Coffey et al.
patent: 2283280 (1999-02-01), None
patent: 2360833 (2000-08-01), None
patent: WO94/18992 (1994-09-01), None
patent: WO94/25627 (1994-11-01), None
patent: WO96/07322 (1996-03-01), None
patent: WO99/18799 (1999-04-01), None
patent: WO 00/50051 (2000-08-01), None
Mercer University Mercer University Home page: 1996, pp. 1-2.
Willian et al. Cancer Immunol. Immunother. 1986, vol. 23 (2), pp. 87-92.
Furtes et al. Current Medicine Chemistry 2003, vol. 10, pp. 257-266.
Orr et al. Oncogen 20003, vol. 22, pp. 7280-7295.
Bona et al. Chaper II, p. 331-334 in Textbook of Immunology, edited by Bona et al. 1996, Hardwood Academic Publishers.
www. acs.ohio-state.edu/units/cancer/handbook/resist.pdf.
Zhang et al. Gene Ther. 2000, vol. 7, pp. 2041-2050.
Prigen et al. J. Biologic. Chemistr. 1996, vol. 271, No. 41, pp. 25635-25645.
Smith et al. Exp. Opin. Invest. Drugs, 2000, vol. 9, No. 2, pp. 311-327.
Liu YB. Zhonghua yi Xue Za Zhi 1993, vol. 73, No. 9, pp. 552-554 and 556. ABSTRACT provided only.
www. acs.ohio-state.edu/units/cancer/handbook/resist.pdf, May 13, 2004.
Andreansky, S.A., et al., “The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors”,Proc. Natl. Acad. Sci. 93(21):11313-11318 (1996).
Bar-Eli, N., et al., “Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells”,J. Cancer Res. Clin. Oncol. 122: 409-415 (1996).
Bergmann, M., et al., “A Genetically Engineered Influenza A Virus withras-Dependent Oncolytic Properties”,Cancer Res. 61:8188-8193 (2001).
Bischoff Jr. et al., “An Adenovirus Mutant that Replicates Selectively in p53-Deficient Human Tumor Cells”,Science274(5286):373-6 (1996).
Blagoslelonny, M.V., et al., “in vitro Evaluation of ap53-Expressing Adenovirus as an Anti-Cancer Drug”,Int. J. Cancer67(3):386-392 (1996).
Borst et al., “A Family of Drug Transporters: the Multidrug Resistance-Associated Proteins”,J. Natl. Cancer Inst. 92(16): 1295-1302 (2000).
Chandran and Nibert, “Protease Cleavage of Reovirus Capsid Protein μ1/μ1C is Blocked by Alkyl Sulfate Detergents, Yielding a New Type of Infectious Subvirion Particle”,J. of Virology72(1):467-75 (1998).
Chang et al., “Rescue of Vaccinia Virus Lacking the E3L Gene by Mutants of E3L”,J. Virol. 69:6605-6608 (1995).
Chang et al., “TheE3Lgene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase”,Proc. Natl. Acad. Sci. 89:4825-4829 (1992).
Chang et al., “Identification of a Conserved Motif that is Necessary for Binding of the Vaccinia Virus E3L Gene Products to Double-Stranded RNA”,Virol. 194:537-547 (1993).
Coffey, M.C., et al., “Reovirus Therapy of Tumors with Activated Ras Pathway”,Science282: 1332-1334 (1998).
DeVita, Jr., “The Relationship Between Tumor Mass and Resistance to Chemotherapy. Implications for Surgical Adjuvant Treatment of Cancer”,Cancer51:1209-1220 (1983).
Duncan et al., “Conformational and Functional Analysis of the C-Terminal Globular Head of the Reovirus Cell Attachment Protein”,Virology182(2):810-9 (1991).
Farassati, F., et al., “Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1”,Nat. Cell Biol. 3(8):745-750 (2001).
Fueyo, J., et al., “A Mutant Oncolytic Adenovirus Targeting the Rb Pathway Produces Anti-Glioma Effect in Vivo”,Oncogene19(1):2-12 (2000).
Grant et al., “Overexpression of Multidrug Resistance-Associated Protein (MRP) Increases Resistance to Natural Product Drugs”,Cancer Res. 54: 357-361 (1994).
Heise, C. et al., “Replication-selective adenoviruses as oncolytic agents”,J. Clin. Invest. 105(7):847-51 (2000).
Kawagishi-Kobayashi, M. et al., “Regulation of the Protein Kinase PKR by the Vaccinia Virus Pseudosubstrate Inhibitor K3L is Dependent on Residues Conserved between the K3L Protein and the PKR Substrate eIF2α”,Mol. Cell. Biol. 17:4146-4158 (1997).
Khuri, et al., “A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer”,Nat Med6(8):862-3 (2000).
Mah et al., “The N-Terminal Quarter of Reovirus Cell Attachment Protein σ1 Possesses Intrinsic Virion-Anchoring Function”,Virology179(1):95-103 (1990).
Nemunaitis, J., “Oncolytic viruses”,Invest. New Drugs17:375-386 (1999).
Pastan and Gottesman, “Multidrug Resistance”,Annu. Rev. Med. 42: 277-286 (1991).
Reichard, K.W., et al., “Newcastle Disease Virus Selectively Kills Human Tumor Cells”,J. of Surgical Research52:448-453 (1992).
Romano et al., “Inhibition of Double-Stranded RNA-Dependent Protein Kinase PKR by Vaccinia Virus E3: Role of Complex Formation and hte E3 N-Terminal Domain”,Mol. Cell. Bio. 18(12):7304-7316 (1998).
Sharp et al., “The Vaccinia Virus E3L Gene Product Interacts with both the Regulatory and the Substrate Binding Regions of PKR: Implications for PKR Autoregulation”,Virology250:302-315 (1998).
Smith, R.E., et al., “Polypeptide Components of Virions, Top Component and Cores of Reovirus Type 3”,Virology, 39:791-800 (1969).
Stojdl, D.F., et al., “Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus”,Nat. Med. 6(7):821-825 (2000).
Strong, J.E., et al., “The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus”,EMBO J. 17:3351-3362 (1998).
Turner and Duncan, “Site-Directed Mutagenesis of the C-terminal Portion of Reovirus Protein σ1: Evidence for a Conformation-Dependent Receptor Binding Domain”,Virology186(1):219-27 (1992).
Yoon, S.S., et al., “An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma”,FASEB J. 14:301-311(2000).
Zorn, U. et al., “Induction of Cytokines and Cytotoxicity against Tumor Cells by Newcastle Disease Virus”,Cancer Biotherapy9(3):22-235 (1994).
Fujiwara, T., et al., Induction of Chemosensitivity in Human Lung Cancer Cells in Vivo by Adenovirus-mediated Transfer of the Wild-Typep53Gene1,Cancer Research54:2298-2291 (1994).
Heise, C., et al., Efficacy with a Replication-selective Adenoviurs Plus Cisplatin-based Chemotherapy: Dependence on Sequencing but not p53 Functional Status or Route of Administration,Clinical Cancer Research6:4908-4914 (2000).
Kirn, D., Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer,Oncogene19:6660-6669 (2000).
Bryson, J.S. and D.C. Cox, “Characteristics of reovirus-mediated chemoimmunotherapy of murine L1210 leukemia”, Cancer Immunol. Immunother. 26: 132-138 (1988).
Steele, T. A. and Cox, D. C., “Reovirus type 3 chemoimmunotherapy of murine lymphoma is abrogated by cyclosporin”, Cancer Biotherapy 10(4): 307-315 (1995).
Rayter, S. I. et al., “p21rasmediates control of IL-2 gene promoter function in T cell activation”, EMBO Journal 11(12): 4549-4556 (1992).
Baldari, C. T., et al., “Interleukin-2 promoter activation in T-cells expressing activated Ha-ras”, J. Biological Chemistry 267(7): 4289-4291 (1992).
Umezawa K. et al., “Isolation of a new vinca alkaloid from the leaves ofErvantimia microphyllaas an inhibitor ofrasfunctions
Coffey Matthew C.
Thompson Bradley G.
Campell Bruce R.
Li Bao Qun
Oncolytics Biotech Inc.
LandOfFree
Sensitization of chemotherapeutic agent resistant neoplastic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sensitization of chemotherapeutic agent resistant neoplastic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sensitization of chemotherapeutic agent resistant neoplastic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3752751